130 related articles for article (PubMed ID: 34952433)
1. Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK).
Fu T; Zuo Y; Zhong Z; Chen X; Pan Z
Eur J Med Chem; 2022 Feb; 229():114051. PubMed ID: 34952433
[TBL] [Abstract][Full Text] [Related]
2. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S
Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2,5-diaminopyrimidine derivatives as the first series of selective monomeric degraders of B-lymphoid tyrosine kinase.
Fu T; Zuo Y; Xue G; Zhou D; Pan Z
Eur J Med Chem; 2023 Aug; 256():115460. PubMed ID: 37163946
[TBL] [Abstract][Full Text] [Related]
4. Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine.
Kwarcinski FE; Fox CC; Steffey ME; Soellner MB
ACS Chem Biol; 2012 Nov; 7(11):1910-7. PubMed ID: 22928736
[TBL] [Abstract][Full Text] [Related]
5. Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors.
Francini CM; Musumeci F; Fallacara AL; Botta L; Molinari A; Artusi R; Mennuni L; Angelucci A; Schenone S
Molecules; 2018 Sep; 23(9):. PubMed ID: 30227617
[TBL] [Abstract][Full Text] [Related]
6. Dysfunctional BLK in common variable immunodeficiency perturbs B-cell proliferation and ability to elicit antigen-specific CD4+ T-cell help.
Compeer EB; Janssen W; van Royen-Kerkhof A; van Gijn M; van Montfrans JM; Boes M
Oncotarget; 2015 May; 6(13):10759-71. PubMed ID: 25926555
[TBL] [Abstract][Full Text] [Related]
7. Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening.
Lin LG; Xie H; Li HL; Tong LJ; Tang CP; Ke CQ; Liu QF; Lin LP; Geng MY; Jiang H; Zhao WM; Ding J; Ye Y
J Med Chem; 2008 Aug; 51(15):4419-29. PubMed ID: 18610999
[TBL] [Abstract][Full Text] [Related]
8. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S
Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826
[TBL] [Abstract][Full Text] [Related]
9. 'Piperazining' the catalytic gatekeepers: unraveling the pan-inhibition of SRC kinases; LYN, FYN and BLK by masitinib.
Aljoundi AK; Agoni C; Olotu FA; Soliman ME
Future Med Chem; 2019 Sep; 11(18):2365-2380. PubMed ID: 31516031
[No Abstract] [Full Text] [Related]
10. Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
Lin J; Shen W; Xue J; Sun J; Zhang X; Zhang C
Eur J Med Chem; 2012 Sep; 55():39-48. PubMed ID: 22818848
[TBL] [Abstract][Full Text] [Related]
11. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ
ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase.
Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H
Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525
[TBL] [Abstract][Full Text] [Related]
13. GRID and docking analyses reveal a molecular basis for flavonoid inhibition of Src family kinase activity.
Wright B; Watson KA; McGuffin LJ; Lovegrove JA; Gibbins JM
J Nutr Biochem; 2015 Nov; 26(11):1156-65. PubMed ID: 26140983
[TBL] [Abstract][Full Text] [Related]
14. Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors.
Francini CM; Fallacara AL; Artusi R; Mennuni L; Calgani A; Angelucci A; Schenone S; Botta M
ChemMedChem; 2015 Dec; 10(12):2027-41. PubMed ID: 26514807
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment.
Cui Z; Chen S; Wang Y; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Aug; 136():372-381. PubMed ID: 28525838
[TBL] [Abstract][Full Text] [Related]
16. Substrate activity screening with kinases: discovery of small-molecule substrate-competitive c-Src inhibitors.
Breen ME; Steffey ME; Lachacz EJ; Kwarcinski FE; Fox CC; Soellner MB
Angew Chem Int Ed Engl; 2014 Jul; 53(27):7010-3. PubMed ID: 24797781
[TBL] [Abstract][Full Text] [Related]
17. ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases.
Nam NH; Lee S; Ye G; Sun G; Parang K
Bioorg Med Chem; 2004 Nov; 12(22):5753-66. PubMed ID: 15498652
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine.
Du G; Rao S; Gurbani D; Henning NJ; Jiang J; Che J; Yang A; Ficarro SB; Marto JA; Aguirre AJ; Sorger PK; Westover KD; Zhang T; Gray NS
J Med Chem; 2020 Feb; 63(4):1624-1641. PubMed ID: 31935084
[TBL] [Abstract][Full Text] [Related]
19. A novel BLK-induced tumor model.
Petersen DL; Berthelsen J; Willerslev-Olsen A; Fredholm S; Dabelsteen S; Bonefeld CM; Geisler C; Woetmann A
Tumour Biol; 2017 Jul; 39(7):1010428317714196. PubMed ID: 28670978
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of 1,4-disubstituted 1,2,3-triazole Derivatives Using Click Chemistry and their Src Kinase Activities.
Lebeau A; Abrioux C; Bénimèlis D; Benfodda Z; Meffre P
Med Chem; 2016; 13(1):40-48. PubMed ID: 27041552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
